Back to News
Market Impact: 0.3
Rhythm Amends LG Chem Deal, Secures Up To $750 Million Financing For Obesity Pipeline
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Rhythm Pharmaceuticals amended its licensing agreement with LG Chem for bivamelagon, an investigational oral therapy for rare obesity disorders, and secured access to up to $750 million in financing to support the program and its broader portfolio. The provided article text does not specify the financing terms or the changes to the licensing agreement.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
RYTM0.45
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge